Core Viewpoint - 康基医疗 is undergoing privatization through an agreement with Knight Bidco Limited, which will result in the company becoming a wholly-owned subsidiary and delisting from the Hong Kong Stock Exchange [1] Group 1: Stock Performance - 康基医疗's stock opened over 5% higher upon resumption of trading, currently up 5.46% at HKD 8.88, with a trading volume of HKD 7.9787 million [1] Group 2: Privatization Details - The privatization will occur at a cancellation price of HKD 9.25, representing a premium of approximately 9.9% over the last trading day's closing price of HKD 8.42 [1] - The company cited ongoing pressure on transaction prices and limited liquidity of shares as reasons for the privatization, which will alleviate short-term financial performance pressures [1] Group 3: Strategic Focus - The decision to privatize is aimed at reducing the costs associated with maintaining a public listing, as the benefits of remaining listed are deemed limited [1] - This move is expected to allow the company to concentrate on strategic goals that require additional resource allocation for sustainable future growth [1]
康基医疗复牌高开逾5% 公司获溢价约9.9%提私有化 将在联交所撤销上市